• World
    • Africa
    • Asia Pacific
    • Central & South Asia
    • Europe
    • Latin America & Caribbean
    • Middle East & North Africa
    • North America
  • Coronavirus
  • Politics
    • US Election
    • US politics
    • Joe Biden
    • Brexit
    • European Union
    • India
    • Arab world
  • Economics
    • Finance
    • Eurozone
    • International Trade
  • Business
    • Entrepreneurship
    • Startups
    • Technology
  • Culture
    • Entertainment
    • Music
    • Film
    • Books
    • Travel
  • Environment
    • Climate change
    • Smart cities
    • Green Economy
  • Global Change
    • Education
    • Refugee Crisis
    • International Aid
    • Human Rights
  • International Security
    • ISIS
    • War on Terror
    • North Korea
    • Nuclear Weapons
  • Science
    • Health
  • 360 °
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice
  • About
  • FO Store
Sections
  • World
  • Coronavirus
  • Politics
  • Economics
  • Business
  • Culture
  • Sign Up
  • Login
  • Publish

Make Sense of the world

Unique insight from 2,000+ contributors in 80+ Countries

Close

The Changing Role of Pharmaceuticals in China and the United States

By Adam Powell • Jun 21, 2012

The way that the United States and China currently spend their healthcare dollars differs sharply.

In China, about half of healthcare spending is on pharmaceuticals, while in the United States only 10% is. Both nations are in the process of undergoing healthcare reform. While America is implementing the Affordable Care Act, aimed at decreasing healthcare utilization, China is implementing its 12th Five-Year Plan, which contains a number of healthcare provisions aimed at increasing healthcare utilization. Given the policies currently being pursued by both nations, it is likely that their pharmaceutical spending patterns will head towards convergence, with Americans spending a relatively larger share on pharmaceuticals, and Chinese spending a relatively smaller share.

Historically, the American and Chinese healthcare systems have had somewhat different strengths. The American system has relied on using highly-trained clinicians to provide expensive reactive care to a small percentage of the population, while the Chinese system has relied on using clinicians with wider variation in training to provide care that is more focused on prevention and is more affordable. This dissimilarity in provider infrastructure is one of the causes of the different use of pharmaceuticals in the two countries.

As a result of the different focuses of the two healthcare systems, healthcare spending is 17.4% of America’s GDP and 4.6% of China’s GDP. Heavy reliance on pharmaceuticals can lower healthcare system costs, as generics have almost no marginal cost, and it often costs less to administer pharmaceuticals than the physician services they sometimes replace. For instance, antidepressants are a lower cost, albeit imperfect substitute for some forms of psychiatric services. Pharmaceuticals likewise can be administered with less training and time. While often cheaper, pharmaceuticals do not always provide better outcomes than physician services, and often carry side-effects.

China’s reliance on pharmaceuticals has multiple origins. While high pharmaceutical use is in part motivated by the design of China’s healthcare delivery system, there are also other factors at play. Currently, Chinese public hospitals (the vast majority of hospitals) operate under price controls. Prices will need to be increased in order for hospitals to be able to sustain themselves solely on healthcare services. While physicians cannot officially charge more than the set prices to patients, they can derive revenue from other sources. One legal source is through the sale of pharmaceuticals. While American physicians cannot dispense the drugs they prescribe, Chinese physicians currently can. This has created a financial incentive for overprescribing which may be impacting treatment decisions.

Recognizing this issue, the Central Committee of the Communist Party of China has called for the separation of dispensing from prescribing in public hospitals in its 12th Five-Year Plan, which guides policy development from 2011 to 2016. Although the integration of dispensing and prescribing makes sense within the context of Traditional Chinese Medicine due to the personalized nature of treatment, it has become clear that it is problematic within the context of allopathic medicine. While this separation will have a substantial financial impact on Chinese hospitals, Minister of Health Chen Zhu is working to ameliorate this problem through increasing the schedule of prices that hospitals may charge.

Meanwhile, in the United States, pharmaceuticals are becoming more affordable to Americans, as the Affordable Care Act increases prescription drug coverage for both seniors and the poor through requiring insurers and drug manufacturers to provide rebates and greater cost sharing. Growing access to health insurance without commensurate growth in the number of physicians is creating a physician shortage. As a result, Americans may have to rely on a more varied set of providers, as Chinese do today. Pharmaceuticals may likewise play a greater role both due to the substantially lower cost of generics relative to physician services, and due to the shortage in physicians available to provide services. Thus, America’s use of pharmaceuticals may become more Chinese while China’s use of pharmaceuticals becomes more American. Moving forward, lessons from China’s past may increasingly become relevant to America’s future.

The views expressed in this article are the author’s own and do not necessarily reflect Fair Observer’s editorial policy.

Share Story
Categories360° Analysis, Asia Pacific, North America
Join our network of more than 2,000 contributors to publish your perspective, share your story and shape the global conversation. Become a Fair Observer and help us make sense of the world.

READ MORE IN THIS 360° SERIES

Sifting Through the Fog: The Affordable Care Act Decision
By Yuri Fuchs • Jul 12, 2012
Health Care in the United States and China
By Jeffrey Chen • Jun 21, 2012
Chinese and American Healthcare Systems: A Comparison
By Adam Powell • Mar 18, 2012
What Can We Do?
By Matthew Mireles • Feb 10, 2012
Waste of Medicines
By Matthew Mireles • Jan 20, 2012
Misuse and Abuse of Medicines
By Matthew Mireles • Jan 10, 2012
Medicines: The Social and Public Health Costs
By Matthew Mireles • Jan 08, 2012

Leave a Reply Cancel reply

You must be logged in to post a comment.

Post navigation

Previous PostPrevious Elections in Kyrgyzstan and the Pluralization of Politics
Next PostNext Don’t We Like Cleaner Cities?
Subscribe
Register for $9.99 per month and become a member today.
Publish
Join our community of more than 2,500 contributors to publish your perspective, share your narrative and shape the global discourse.
Donate
We bring you perspectives from around the world. Help us to inform and educate. Your donation is tax-deductible.

Explore

  • About
  • Authors
  • FO Store
  • FAQs
  • Republish
  • Privacy Policy
  • Terms of Use
  • Contact

Regions

  • Africa
  • Asia Pacific
  • Central & South Asia
  • Europe
  • Latin America & Caribbean
  • Middle East & North Africa
  • North America

Topics

  • Politics
  • Economics
  • Business
  • Culture
  • Environment
  • Global Change
  • International Security
  • Science

Sections

  • 360°
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice

Daily Dispatch


© Fair Observer All rights reserved
We Need Your Consent
We use cookies to give you the best possible experience. Learn more about how we use cookies or edit your cookie preferences. Privacy Policy. My Options I Accept
Privacy & Cookies Policy

Edit Cookie Preferences

The Fair Observer website uses digital cookies so it can collect statistics on how many visitors come to the site, what content is viewed and for how long, and the general location of the computer network of the visitor. These statistics are collected and processed using the Google Analytics service. Fair Observer uses these aggregate statistics from website visits to help improve the content of the website and to provide regular reports to our current and future donors and funding organizations. The type of digital cookie information collected during your visit and any derived data cannot be used or combined with other information to personally identify you. Fair Observer does not use personal data collected from its website for advertising purposes or to market to you.

As a convenience to you, Fair Observer provides buttons that link to popular social media sites, called social sharing buttons, to help you share Fair Observer content and your comments and opinions about it on these social media sites. These social sharing buttons are provided by and are part of these social media sites. They may collect and use personal data as described in their respective policies. Fair Observer does not receive personal data from your use of these social sharing buttons. It is not necessary that you use these buttons to read Fair Observer content or to share on social media.

 
Necessary
Always Enabled

These cookies essential for the website to function.

Analytics

These cookies track our website’s performance and also help us to continuously improve the experience we provide to you.

Performance
Uncategorized

This cookie consists of the word “yes” to enable us to remember your acceptance of the site cookie notification, and prevents it from displaying to you in future.

Preferences
Save & Accept